Keros Therapeutics (KROS) Amortization of Deferred Charges (2019 - 2025)
Keros Therapeutics (KROS) posted Amortization of Deferred Charges of $622000.0 for Q4 2025, up 2.13% on a QoQ basis from $609000.0 in Q3 2025, and up 8.74% year-over-year from $572000.0 in Q4 2024.
Keros Therapeutics (KROS) Amortization of Deferred Charges (2019 - 2025) Analysis & Trends
Keros Therapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $622000.0 for Q4 2025.
- Quarterly Amortization of Deferred Charges rose 8.74% year-over-year to $622000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 32.42% YoY) and the FY2025 annual result came in at $2.4 million, up 32.42% from the prior year.
- Amortization of Deferred Charges was $622000.0 for Q4 2025 at Keros Therapeutics, up from $609000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $622000.0 in Q4 2025 and bottomed at $99000.0 in Q1 2021.
- A 5-year average of $362150.0 and a median of $340000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges surged 157.14% — and 2024, when it tumbled 35.06%.
- Keros Therapeutics' Amortization of Deferred Charges stood at $198000.0 in 2021, then jumped by 62.12% to $321000.0 in 2022, then increased by 4.36% to $335000.0 in 2023, then surged by 70.75% to $572000.0 in 2024, then rose by 8.74% to $622000.0 in 2025.
- Business Quant data shows KROS's Amortization of Deferred Charges at $622000.0 in Q4 2025, $609000.0 in Q3 2025, and $595000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Keros Therapeutics | 383.75 Mn | 96.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 622,000.00 |
| Dec 31, 2025 | 622,000.00 |
| Sep 30, 2025 | 609,000.00 |
| Sep 30, 2025 | 609,000.00 |
| Jun 30, 2025 | 595,000.00 |
| Jun 30, 2025 | 595,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Sep 30, 2024 | 563,000.00 |
| Sep 30, 2024 | 563,000.00 |
| Jun 30, 2024 | 346,000.00 |
| Jun 30, 2024 | 346,000.00 |
| Mar 31, 2024 | 339,000.00 |
| Mar 31, 2024 | 339,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Sep 30, 2023 | 341,000.00 |
| Sep 30, 2023 | 341,000.00 |